Leuprolide Active Not Recruiting Phase 2 Trials for High Risk Prostate Cancer / Adenocarcinoma, Prostate / Prostate Cancer Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02268175Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
NCT02274779Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer
NCT02064582Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
NCT02772588AASUR in High Risk Prostate Cancer
NCT02716974A Study of Definitive Therapy to Treat Prostate Cancer
NCT02742675Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
NCT03043807A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
NCT00329043Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
NCT03093272A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
NCT02903368Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
NCT00003915Chemotherapy and Hormone Therapy in Treating Patients With Prostate Cancer